Cargando…

Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study

Detalles Bibliográficos
Autores principales:	Blanchi, Julie, Laroche‐Clary, Audrey, Le Loarer, François, Bonhomme, Benjamin, Italiano, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009659/ https://www.ncbi.nlm.nih.gov/pubmed/36738132 http://dx.doi.org/10.1002/cac2.12389

Ejemplares similares

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020)

Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas
por: Crombé, Amandine, et al.
Publicado: (2022)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications
por: Ben-Ami, Eytan, et al.
Publicado: (2020)

Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft‐tissue sarcomas
por: Blanchi, Julie, et al.
Publicado: (2023)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
por: Fourneaux, Benjamin, et al.
Publicado: (2019)

Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
por: Fourneaux, Benjamin, et al.
Publicado: (2019)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

Local and Metastatic Relapse Features in Patients After a Primary Soft Tissue Sarcoma: Advocating for a Better-Tailored Follow-Up
por: Blaye, Céline, et al.
Publicado: (2019)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas
por: Verbeke, S., et al.
Publicado: (2021)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

Intensity harmonization techniques influence radiomics features and radiomics-based predictions in sarcoma patients
por: Crombé, Amandine, et al.
Publicado: (2020)

High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies
por: Toulmonde, Maud, et al.
Publicado: (2020)

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021)

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications
por: Spalato-Ceruso, M, et al.
Publicado: (2023)

Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
por: Kantidakis, Georgios, et al.
Publicado: (2022)

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
por: Spalato-Ceruso, Mariella, et al.
Publicado: (2022)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies
por: Roy, Shomereeta, et al.
Publicado: (2020)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications
por: Fourneaux, Benjamin, et al.
Publicado: (2016)

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
por: Dadone-Montaudié, Bérengère, et al.
Publicado: (2020)

Significance of Circulating Tumor Cells in Soft Tissue Sarcoma
por: Nicolazzo, Chiara, et al.
Publicado: (2015)

Prognostic factors for survival in soft tissue sarcoma.
por: el-Jabbour, J. N., et al.
Publicado: (1990)

Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas
por: Sorbye, Sveinung W., et al.
Publicado: (2011)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Circulating tumour-derived DNA in metastatic soft tissue sarcoma
por: Eastley, Nicholas C., et al.
Publicado: (2018)

Whole‐exome sequencing in clear cell sarcoma of soft tissue uncovers novel prognostic categorization and drug targets
por: Li, Jingjing, et al.
Publicado: (2021)

Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
por: Italiano, Antoine, et al.
Publicado: (2021)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma
por: Smeland, Eivind, et al.
Publicado: (2012)

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
por: Merry, Eve, et al.
Publicado: (2021)

Prognostic Value of PLAGL1-Specific CpG Site Methylation in Soft-Tissue Sarcomas
por: Peille, Anne-Lise, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1djo8f4jonhl7kh3io8ljm1tqb